Louis J J, Guibaud P, Dumoulin R, Parchoux B, Zabot M T, Bureau J, Baltassat P, Frederich A, Larbre F
Pediatrie. 1984 Dec;39(8):619-33.
The effect of cysteamine was studied in 6 children with nephropathic cystinosis. In 3 of them an in vitro study on fibroblasts was performed. The cystine content of fibroblasts was immediately diminished (about 90% of total cystine content) as soon as the concentration of cysteamine in the medium was greater than or equal to 0,1 mmole/l. In vivo, 50 to 89 mg/kg/day of cysteamine was administered for 9 to 37 months (mean 21,3). There was no adverse reaction. In all cases a dramatic decline in leukocyte cystine level was observed (in 5 cases the level was within the range seen in clinically unaffected heterozygotes). Growth was not improved. The renal function was stabilised in 3 cases. Photophobia which was present in 4 children decreased in 2 cases or disappeared in 2 cases.
对6名患有肾病性胱氨酸病的儿童进行了半胱胺效果的研究。其中3名儿童进行了成纤维细胞的体外研究。一旦培养基中半胱胺的浓度大于或等于0.1毫摩尔/升,成纤维细胞中的胱氨酸含量立即减少(约占总胱氨酸含量的90%)。在体内,给予半胱胺50至89毫克/千克/天,持续9至37个月(平均21.3个月)。未出现不良反应。在所有病例中均观察到白细胞胱氨酸水平显著下降(5例患者的水平在临床未受影响的杂合子所见范围内)。生长情况未得到改善。3例患者的肾功能得以稳定。4名儿童存在的畏光症状,2例有所减轻,2例消失。